At-Home Prescription Neuromodulation
Clinician-supervised but patient-operated electrical brain stimulation hardware moves neuromodulation therapy out of the clinic and into the home for psychiatric indications.
Developed mainly in: SwedenImpacting: North America and Europe
Flow Neuroscience, based in Malmö, Sweden, began US prescription sales of FL-100, a transcranial direct current stimulation headset patients use at home under clinician supervision. The FDA-authorised device treats moderate-to-severe major depressive disorder in adults aged 18+ who are not medication-refractory, either alone or alongside antidepressants. Roughly 19.7 million US adults had a major…
This is one of 24 signals scored in our latest scan.
Track Them Free For 14 Days →Since we flagged this
First flagged
17 September 2026 · score 7.0/10
Corroborating sources since flagging
20
Latest signals
Tracked from 2 signals, each traced to its source.
- Home-use brain stimulation headset for depression clears FDA and reaches US prescription market
Globenewswire · 17 Sept 2026
- At-home brain stimulation headset cleared by FDA reaches US depression patients
Biospace · 17 Sept 2026
In the full record
Evolution
Score over time, Score Jumps and how the evidence built up since the first signal.
Thesis
Paradigm Shift, Commercial Viability, signal strength and the driver of the change.
Why this innovation matters
The full analysis: what is shifting, who is affected and the second-order effects.
Forecasted Hypothesis
What would strengthen this innovation, and what would weaken it.
Exposure
Companies and publicly listed stock symbols linked to this innovation.
Every signal
Each signal with its date, score, flags and original source.
Open the full record free for 14 days → No card needed.
More in Healthcare
Other innovations the engine is currently tracking in this industry.
- Image-Based Cancer Prognostic Modelling6.5/ 10 · 2 signals
- Hospital-At-Home Continuous Vital-Sign Patches5.0/ 10 · 2 signals
- Automated Quantitative Imaging Biomarkers5.5/ 10 · 2 signals
- Prescription Digital Therapeutics7.0/ 10 · 10 signals
- Oral Small-Molecule GLP-1 Agonists7.8/ 10 · 6 signals
- Clinical-Grade Wearable Biosensing6.0/ 10 · 2 signals
Track every innovation, free for 14 days
Full Analyst access from the first day. No card. Then subscribe to keep it.
- The radar: every innovation, ranked by Disruption Score
- Tracked evolution: score over time, Score Jumps and how the evidence built up
- Thesis and analysis: Commercial Viability, Paradigm Shift, why it matters, what would change it
- Geography: where each innovation is developed and where it has impact
- Exposure: the companies and public stock symbols behind each innovation
- Every signal with its source, and what moved since your last visit
- Email alerts when an innovation moves: First Signal, Score Jump and briefings
Disclaimer: The information provided on this page is for educational and informational purposes only. It does not constitute financial advice, investment recommendations, or an offer to buy or sell securities. Stock data shown is illustrative and may not reflect real-time prices. Always conduct your own research and consult a qualified financial advisor before making investment decisions. Past performance does not guarantee future results.